Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety, tolerability, and pharmacokinetics study of BAL2420 in healthy adults
NL-OMON58850Phase 1Recruiting
- Sponsor
- Basilea Pharmaceutica
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of BAL2420 in Gram-negative bacterial infection, sponsored by Basilea Pharmaceutica. Started Mar 2026; status: recruiting.
02
Drugs
BAL2420
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NL-OMON58850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58850.